Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Primary Outcome Measures Incidence of DLTs (dose-limiting toxicity) [ Time Frame: 6 weeks (42 days) ] Eligibility Inclusion Criteria Signed informed consent Male or female subjects ≥ 18 years of age ECOG PS (Eastern Cooperative Oncology Group Performance Status) of 0 or 1 Subjects with advanced, histologically or cytologically confirmed epithelioid mesothelioma (pleural or peritoneal) or serous ... [More >>]

Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer (STEP PC)

Primary Outcome Measures Establish that stepped PC is non-inferior to early integrated PC in improving patients' QOL, as measured by the FACT-L [ Time Frame: 24 Weeks ] Quality of life as measured by the Functional Assessment of Cancer Therapy-Lung Secondary Outcome Measures Assess whether stepped PC is non-inferior to early integrated PC with ... [More >>]

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Primary Outcome Measures Safety and tolerability [ Time Frame: 4 months after last patient has enrolled ] Reporting of adverse events with grade 3 and grade 4 fraction at each dose level Maximum tolerated dose [ Time Frame: 21 days after the last patient in the dose escalation cohort has initiated study theapy ... [More >>]

MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. (MesoTRAP)

Primary Outcome Measures To measure the standard deviation of Visual Analogue Scale scores for breathlessness [ Time Frame: Daily from randomisation to 12 months ] The Visual Analogue Scale (VAS) is a 100mm line for patients to record the severity of a their breathlessness where 0mm is "No breathlessness at all" and ... [More >>]

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Primary Outcome Measures Overall response rate [ Time Frame: 3 years ] defined by modified RECIST 1.1 for mesothelioma Eligibility Inclusion Criteria Patient willing and able to provide written informed consent for the trial. Patient age ≥ 18 at time of consent. Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM). No plans for surgical resection. PD-L1 expression ... [More >>]

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Primary Outcome Measures Progression-free survival of the participants(PFS) [ Time Frame: 24 months ] From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first. Secondary Outcome Measures Overall survival of the participants(OS) [ Time Frame: 24 ... [More >>]

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Primary Outcome Measures Phase I part: Incidence of dose limiting toxicities (DLTs) [ Time Frame: 30 months ] A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications ... [More >>]

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Primary Outcome Measures Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability [ Time Frame: 6 months ] Secondary Outcome Measures To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective ... [More >>]

Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

Primary Outcome Measures Dose Limiting Toxicity [ Time Frame: Up to 4 weeks ] Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version) [ Time Frame: Screening through 4 weeks after study completion, an average ... [More >>]

Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders

Primary Outcome Measures Signal to Noise Ratio [ Time Frame: 2 years ] The primary objective of this study is to determine an optimized set of scan parameters that will produce clear, anatomically and clinically relevant images of the lungs for healthy participants and various types of lung disorder participants, and using ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.